ANI Pharmaceuticals Launches FDA-Approved 10 mg/20 mg Isosorbide Mononitrate Generics
ANI Pharmaceuticals received FDA approval for its ANDA and launched generic Isosorbide Mononitrate Tablets USP in 10 mg and 20 mg strengths. The limited-competition product targets the reference listed drug Monoket® and bolsters the company’s Generics business pipeline.
1. FDA Approval and Product Launch
ANI Pharmaceuticals secured final FDA approval for its Abbreviated New Drug Application and immediately launched Isosorbide Mononitrate Tablet USP in 10 mg and 20 mg strengths, entering a segment previously dominated by the branded Monoket® product.
2. Generics Business Implications
The new tablet enhances ANI’s Generics division by adding a high-demand cardiovascular therapy, leveraging the company’s U.S.-based manufacturing and R&D expertise to capture market share from existing branded alternatives.
3. Strategic Outlook
This launch aligns with the company’s strategy of rolling out limited-competition products to drive sustainable revenue growth, strengthen operating margins and maintain a steady cadence of new product introductions in its Generics segment.